Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Conditions
- Colorectal Cancer
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineBiological: cetuximabDrug: CyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: oxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169777
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineBiological: CetuximabDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelBiological: nivolumabDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: leucovorinDrug: nab-paclitaxelDrug: LovazaDrug: OxaliplatinDrug: rituximabRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-061Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169790
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: avelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: cyclophosphamideDrug: 5-Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab paclitaxelBiological: nivolumabDrug: LovazaDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
- Conditions
- Merkel Cell Carcinoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-051Biological: ETBX-061Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167164
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
- Conditions
- Melanoma
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CisplatinDrug: CyclophosphamideDrug: 5-fluorouracilDrug: LeucovorinDrug: nab-paclitaxelBiological: NivolumabDrug: omega-3-acid ethyl estersRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167177
Chemotherapy with or Without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
- Conditions
- Gastric AdenocarcinomaOligometastasisStage IV Esophageal Adenocarcinoma AJCC V7Stage IV Esophageal Cancer AJCC V7Stage IV Gastric Cancer AJCC V7
- Interventions
- Drug: CapecitabineDrug: ChemotherapyProcedure: Conventional SurgeryDrug: FluorouracilRadiation: Radiation Therapy
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03161522
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03158610
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China
Preoperative Radiotherapy and E7046 in Rectum Cancer
- Conditions
- Neoadjuvant Therapy in Rectal Cancer
- Interventions
- Drug: E7046Radiation: Long Course Chemoradiotherapy (LCRT)Radiation: Short Course Radiotherapy (SCRT)Drug: folinic acid/5-FU/oxaliplatin (mFOLFOX-6)Drug: capecitabine
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT03152370
- Locations
- 🇬🇧
The Christie, Manchester, United Kingdom
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Weill Cornell, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.